OBGYN Maternity RSV
Maternity RSV (Respiratory Syncitial Virus) vaccine study in pregnant women between the ages of 18 to 45 years. The study will last a year and to evaluate the immunogenicity of the vaccine in the newborn to prevent Lower respiratory tract infections.
OBGYN Maternity RSV - Summary
Respiratory Syncytial Virus (RSV) is the leading cause of chest infections (pneumonia and bronchiolitis) in young children, and is a major cause of admission to hospital and childhood death worldwide. One possible way to protect the mother and young infant from RSV infection is a vaccine given to women during pregnancy (maternal vaccination), which would pass protection to their unborn child. This may help to prevent RSV in the child's first few months of life when they are most vulnerable to infection.
There are two main aims to this study:
To pre-emptively gauge the knowledge of RSV and potential acceptability of such vaccines amongst pregnant women and healthcare staff working in midwifery and obstetrics, as well as their attitudes (facilitators and barriers) to being involved in hypothetical future research trials.
We also wish to gauge the attitudes to routinely recommended vaccines in pregnancy (pertussis and influenza)
Are you interested in working together with us?
